Clinical trial NCT02278575 - References

Antithrombin III Deficiency — Atenativ Effect on Uterine Blood Flow and Preeclampsia

Citation(s)

•   Aghai E, Brunstein J, Quitt M, Abramovici H, Froom P
  Antithrombin III levels in preeclampsia. Isr J Med Sci. 1990 Mar;26(3):142-3.
•   Heilmann L, Rath W, Pollow K
  Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost. 2007 Jul;13(3):285-91.
•   Hellgren M, Hägnevik K, Robbe H, Björk O, Blombäck M, Eklund J
  Severe acquired antithrombin III deficiency in relation to hepatic and renal insufficiency and intrauterine fetal death in late pregnancy. Gynecol Obstet Invest. 1983;16(2):107-18.
•   Hellgren M, Javelin L, Hägnevik K, Blombäck M
  Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients. Thromb Res. 1984 Aug 15;35(4):459-66.
•   Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, Maki M; BI 51 017 Study Group
  Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost. 2003 Dec;29(6):645-52.
•   Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, Sagara Y, Kajiwara Y, Urata M
  Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group. Thromb Haemost. 2000 Oct;8
•   Paternoster DM, Fantinato S, Manganelli F, Nicolini U, Milani M, Girolami A
  Recent progress in the therapeutic management of pre-eclampsia. Expert Opin Pharmacother. 2004 Nov;5(11):2233-9. Review.
•   Sameshima H, Kodama Y, Ikenoue T, Kajiwara Y
  Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. J Obstet Gynaecol Res. 2008 Feb;34(1):34-9. doi: 10.
•   Weenink GH, Treffers PE, Vijn P, Smorenberg-Schoorl ME, ten Cate JW
  Plasma antithrombin III levels in pre-eclampsia. Clin Exp Hypertens B. 1983;2(1):145-62.

Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia

Details for clinical trial NCT02278575